Valneva (NASDAQ:VALN) Rating Increased to Strong-Buy at TD Cowen

Key Points

• TD Cowen upgraded Valneva to “strong buy,” while other analysts remain mixed; the stock carries a consensus “Moderate Buy” rating and an average price target of $11.98.
• Valneva shares opened at $5.59, well below their 52-week high of $12.25. The company reported a quarterly loss of $0.42 per share on $35.77 million in revenue and continues to post deeply negative profitability metrics.
• Institutional investors own 11.39% of Valneva, with several funds—including JPMorgan Chase and Marex Group—recently establishing new positions.

Valneva (NASDAQ:VALN - Get Free Report) was upgraded by research analysts at TD Cowen to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Valneva from a "strong sell" rating to a "sell" rating in a research report on Monday, June 1st. Guggenheim set a $11.00 price target on Valneva in a report on Thursday, April 16th. The Goldman Sachs Group downgraded Valneva from a "neutral" rating to a "sell" rating and set a $4.90 price target on the stock. in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Valneva in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $11.98.

Valneva Stock Performance

Shares of VALN stock opened at $5.59 on Tuesday. The company has a 50 day moving average price of $5.21 and a 200-day moving average price of $6.98. Valneva has a 52 week low of $4.75 and a 52 week high of $12.25. The firm has a market capitalization of $530.44 million, a PE ratio of -2.99 and a beta of 1.77. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The company had revenue of $35.77 million for the quarter. As a group, equities research analysts expect that Valneva will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VALN. Marex Group plc bought a new stake in shares of Valneva during the second quarter valued at approximately $64,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva in the third quarter worth about $124,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva in the fourth quarter worth about $44,000. Finally, XTX Topco Ltd bought a new position in Valneva during the fourth quarter valued at approximately $94,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source